Scholarlink

Amyotrophic lateral sclerosis (ALS) is classified as an intractable neurodegenerative disease, and no established treatment has yet been developed for sporadic patients. Therefore, there are high hopes for regenerative therapies, including cell therapy. We are developing a treatment that applies bone marrow cells that can be autologously transplanted. In this chapter, we introduce a treatment that combines bone marrow mononuclear cells and mesenchymal stem cells that express growth factors using artificial chromosome vectors. We explain the method of administration to model animals and the evaluation of its effects.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Combination Therapy of Bone Marrow-Derived Mononuclear Cells and Mesenchymal Stem Cells Expressing Growth Factors for Amyotrophic Lateral Sclerosis

  • 实验方案

  • 发表日期：

    2025年

查看全文
  • Tomoya Terashima

摘要

Amyotrophic lateral sclerosis (ALS) is classified as an intractable neurodegenerative disease, and no established treatment has yet been developed for sporadic patients. Therefore, there are high hopes for regenerative therapies, including cell therapy. We are developing a treatment that applies bone marrow cells that can be autologously transplanted. In this chapter, we introduce a treatment that combines bone marrow mononuclear cells and mesenchymal stem cells that express growth factors using artificial chromosome vectors. We explain the method of administration to model animals and the evaluation of its effects.